Unravelling the relationship between degree of disorder and the dissolution behavior of milled glibenclamide.

Milling is an attractive method to prepare amorphous formulations as it does not require the use of solvents and is suitable for thermolabile drugs. One of the key critical quality attributes of milled amorphous formulations is their dissolution behavior. However, there are limited studies that have investigated the relationship between degree of disorder induced by milling and dissolution behavior. The main aim of this study was to identify the analytical technique used to characterize degree of disorder that correlates best with the recrystallization behavior during dissolution of milled glibenclamide samples. Solid state and surface changes during dissolution of milled glibenclamide samples were monitored in order to elucidate the processes that influence the dissolution behavior of milled glibenclamide samples. Glibenclamide was ball milled for different durations and analyzed using X-ray powder diffractometry (XRPD), Raman spectroscopy and differential scanning calorimetry (DSC). Recrystallization during dissolution of the milled amorphous materials was investigated using an in situ Raman setup. SEM was used to monitor the surfaces of the compacts during dissolution. XRPD, Raman spectroscopy and DSC indicated that glibenclamide was fully amorphous after milling for 30, 60, and 120 min, respectively. 'DSC amorphous' (i.e. fully amorphous according to the onset of crystallization obtained from DSC) glibenclamide samples experienced negligible recrystallization which had no effect on the dissolution profiles. Samples that were not 'DSC amorphous' experienced recrystallization which resulted in a decrease in dissolution rate. Unexpected elevated dissolution rate was observed initially during dissolution for samples milled for 15 to 45 min, and this was related to particle loss from surfaces of the disks during dissolution. In conclusion, the onset of crystallization obtained from DSC best predicts the recrystallization of glibenclamide during dissolution. Recrystallization and particle loss from the surface of the dissolution should be considered when interpreting the dissolution data of milled glibenclamide samples.

[1]  C. Strachan,et al.  Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[2]  Bernard Van Eerdenbrugh,et al.  Crystallization tendency of active pharmaceutical ingredients following rapid solvent evaporation--classification and comparison with crystallization tendency from undercooled melts. , 2010, Journal of pharmaceutical sciences.

[3]  J. Rantanen,et al.  Assessment of crystalline disorder in cryo-milled samples of indomethacin using atomic pair-wise distribution functions. , 2011, International journal of pharmaceutics.

[4]  L Yu,et al.  Amorphous pharmaceutical solids: preparation, characterization and stabilization. , 2001, Advanced drug delivery reviews.

[5]  H. Siesler,et al.  Conformational polymorphism of the antidiabetic drug chlorpropamide , 2012 .

[6]  K. Kawakami,et al.  Current status of amorphous formulation and other special dosage forms as formulations for early clinical phases. , 2009, Journal of pharmaceutical sciences.

[7]  Jonathan C Burley,et al.  Investigating the recrystallization behavior of amorphous paracetamol by variable temperature Raman studies and surface Raman mapping. , 2012, Molecular pharmaceutics.

[8]  Siegfried Wartewig,et al.  Pharmaceutical applications of Mid-IR and Raman spectroscopy. , 2005, Advanced drug delivery reviews.

[9]  R. Tan,et al.  Dissolution enhancement of indomethacin via amorphization using co-milling and supercritical co-precipitation processing , 2013 .

[10]  C. Pouton,et al.  Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[11]  T. Rades,et al.  Thermal degradation of amorphous glibenclamide. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[12]  Ashwini Nangia,et al.  Solubility Advantage of Amorphous Drugs and Pharmaceutical Cocrystals , 2011 .

[13]  Chandan Bhugra,et al.  Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. , 2008, Journal of pharmaceutical sciences.

[14]  Jukka Rantanen,et al.  In situ measurement of solvent-mediated phase transformations during dissolution testing. , 2006, Journal of pharmaceutical sciences.

[15]  C. Strachan,et al.  A theoretical and spectroscopic study of co-amorphous naproxen and indomethacin. , 2013, International journal of pharmaceutics.

[16]  V. Caron,et al.  A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone. , 2011, Molecular pharmaceutics.

[17]  Thomas Rades,et al.  Correlating thermodynamic and kinetic parameters with amorphous stability. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[18]  E. Sallam,et al.  Preparation and characterization of a new polymorphic form and a solvate of glibenclamide. , 1997, Acta pharmaceutica Hungarica.

[19]  C. Strachan,et al.  Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[20]  R. Suryanarayanan,et al.  Effect of Preparation Method on Physical Properties of Amorphous Trehalose , 2004, Pharmaceutical Research.

[21]  Christel A. S. Bergström,et al.  Toward in silico prediction of glass-forming ability from molecular structure alone: a screening tool in early drug development. , 2011, Molecular pharmaceutics.

[22]  G. Zografi,et al.  The Quantitative Analysis of Crystallinity Using FT-Raman Spectroscopy , 1998, Pharmaceutical Research.

[23]  M. Suleiman,et al.  Isolation and physicochemical characterization of solid forms of glibenclamide , 1989 .

[24]  C. Strachan,et al.  Effect of different preparation methods on the dissolution behaviour of amorphous indomethacin. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[25]  J. Rantanen,et al.  Enhanced dissolution rate and synchronized release of drugs in binary systems through formulation: Amorphous naproxen-cimetidine mixtures prepared by mechanical activation. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[26]  M. Descamps,et al.  Solid State Amorphization of Pharmaceuticals , 2009 .

[27]  Bernard Van Eerdenbrugh,et al.  A classification system to assess the crystallization tendency of organic molecules from undercooled melts. , 2010, Journal of pharmaceutical sciences.

[28]  Sergey Vyazovkin,et al.  Crystallization kinetics of amorphous nifedipine studied by model-fitting and model-free approaches. , 2003, Journal of pharmaceutical sciences.

[29]  S. Boerrigter,et al.  Investigation of the Milling-Induced Thermal Behavior of Crystalline and Amorphous Griseofulvin , 2010, Pharmaceutical Research.

[30]  R. Pinal,et al.  The nature of crystal disorder in milled pharmaceutical materials , 2008 .

[31]  C. Strachan,et al.  The impact of surface- and nano-crystallisation on the detected amorphous content and the dissolution behaviour of amorphous indomethacin. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[32]  R. Pinal,et al.  Process induced disorder in crystalline materials: differentiating defective crystals from the amorphous form of griseofulvin. , 2008, Journal of pharmaceutical sciences.

[33]  N. Trasi,et al.  Mechanically Induced Amorphization of Drugs: A Study of the Thermal Behavior of Cryomilled Compounds , 2012, AAPS PharmSciTech.

[34]  Robin Taylor,et al.  Mercury: visualization and analysis of crystal structures , 2006 .

[35]  Christel A.S. Bergström,et al.  Early drug development predictions of glass-forming ability and physical stability of drugs. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[36]  Cornelia M Keck,et al.  Challenges and solutions for the delivery of biotech drugs--a review of drug nanocrystal technology and lipid nanoparticles. , 2004, Journal of biotechnology.

[37]  Mo Li,et al.  Formulation of Nanosuspensions as a New Approach for the Delivery of Poorly Soluble Drugs , 2009 .

[38]  M. B. James,et al.  The influence of thermal and mechanical preparative techniques on the amorphous state of four poorly soluble compounds. , 2005, Journal of pharmaceutical sciences.

[39]  C. Strachan,et al.  Investigation of properties and recrystallisation behaviour of amorphous indomethacin samples prepared by different methods. , 2011, International journal of pharmaceutics.

[40]  Z. Iqbal,et al.  Spectroscopic and X-Ray Diffraction Study of Structural Disorder in Cryomilled and Amorphous Griseofulvin , 2011 .

[41]  A. Fahr,et al.  Drug delivery strategies for poorly water-soluble drugs , 2007, Expert opinion on drug delivery.

[42]  M. Descamps,et al.  Grinding of drugs with pharmaceutical excipients at cryogenic temperatures , 2007 .

[43]  G. Regdon,et al.  Quantitative Determination of Crystallinity of α-Lactose Monohydrate by DSC , 2002 .

[44]  K. Chrissafis,et al.  Crystallization kinetics of amorphous , 2003 .